Dublin, July 21, 2025 (GLOBE NEWSWIRE) -- The "Cote d'Ivoire IVD Market by Offering, Technology, Application, Diagnostic Approach, End User - Forecast to 2032" report has been added to ResearchAndMarkets.com's offering.
The growth of this market is driven by the rising burden of infectious diseases, increasing government support and international aid, advancements in diagnostic technologies, and growing health awareness and population growth. Furthermore, public-private partnerships (PPP), growing demand for molecular diagnostics, telemedicine, and point-of-care testing, and increasing awareness of early diagnosis are expected to generate growth opportunities for the stakeholders in this market.
The key players operating in the Cote d'Ivoire IVD market are Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), bioMerieux SA (France), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), QIAGEN N.V. (Netherlands), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc., (U.S.), Illumina, Inc. (U.S.), Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China), The Cote d'Ivoire Medical Research Institute (KEMRI), Biovet Ltd. (India), and Laboratories & Allied Ltd. (Kenya).
By offering, the Cote d'Ivoire IVD is segmented into reagents & kits, instruments, and software & services. In 2025, the reagents & kits segment is expected to account for the largest share of 84.2% of the Cote d'Ivoire IVD market. The large market share of this segment is attributed to the recurring use of assays & kits in the detection of various chronic diseases, the commercial availability of a diverse range of reagents & consumables for the diagnosis of various diseases, and the increase in the volume of testing for infectious diseases such as COVID-19 and influenza. Cote d'Ivoire faces a high burden of infectious diseases such as malaria, HIV/AIDS, tuberculosis (TB), and hepatitis. For instance, malaria remains endemic, accounting for a significant portion of outpatient consultations and hospitalizations. This creates a consistent demand for rapid diagnostic tests (RDTs), PCR reagents, and other related kits.
By technology, the Cote d'Ivoire IVD is segmented into immunoassay/immunochemistry, whole blood glucose monitoring, molecular diagnostics, point-of-care diagnostics, biochemistry/clinical chemistry, microbiology, hematology, coagulation & hemostasis, and other IVD technologies. The whole blood glucose monitoring segment is projected to register the highest CAGR during the forecast period of 2025-2032. The high growth of this segment is mainly driven by the growing prevalence of diabetes and rising awareness regarding the availability of self-testing kits for glucose monitoring are major factors driving the growth of this segment.
By application, the Cote d'Ivoire IVD market is segmented into infectious diseases, diabetes, oncology, cardiology, nephrology, autoimmune diseases, and other applications. The cardiology segment is projected to register the highest CAGR during the forecast period. Factors such as rising burden of cardiovascular diseases, increasing lifestyle-related risk factors, increasing demand for early diagnosis & management, limited healthcare infrastructure demands for accessible and affordable testing solutions, government initiatives for spreading awareness of CVD risk factors, and growing adoption of point-of-care testing devices.
Cardiovascular diseases (CVDs) are a significant public health concern in Cote d'Ivoire. According to data published by the World Health Organization (WHO) in 2020, coronary heart disease accounted for 11,073 deaths, representing 6.42% of total deaths in the country. The age-adjusted death rate was 124.19 per 100,000 population, ranking Cote d'Ivoire 74th globally in terms of coronary heart disease mortality.
By diagnostic approach, the Cote d'Ivoire IVD market is categorized into laboratory testing, point-of-care testing, and OTC/self-testing. In 2025, the laboratory testing segment is expected to account for the largest share of the Cote d'Ivoire IVD market. This can be attributed to the widespread reliance on centralized laboratories for comprehensive diagnostic services, which are considered the gold standard for accuracy and reliability. Laboratory testing is essential for the diagnosis and monitoring of a broad range of diseases, including infectious diseases, chronic conditions, and non-communicable diseases, which are prevalent in the region.
By end user, the Cote d'Ivoire IVD market is segmented into diagnostic laboratories, hospitals & clinics, home healthcare, and other end users. In 2025, the diagnostic laboratories segment is expected to account for the largest share of the Cote d'Ivoire IVD market. This dominance is primarily attributed to the increasing demand for accurate and early disease detection, the availability of advanced diagnostic technologies, and the growing number of private and public diagnostic laboratories across the country. Diagnostic laboratories typically offer a broad range of specialized tests and have the infrastructure and expertise required for complex analyses, which enhances their role in disease management.
Key Questions Answered in the Report:
- What is the current revenue generated by Cote d'Ivoire IVD globally?
- At what rate is the Cote d'Ivoire IVD demand projected to grow for the next 5-7 years?
- What are the historical market sizes and growth rates of the Cote d'Ivoire IVD market?
- What are the major factors impacting the growth of this market at the regional and country levels? What are the major opportunities for existing players and new entrants in the market?
- Which segments in terms of offering, technology, application, diagnostic approach, and end user are expected to create major traction for the manufacturers in this market?
- What are the key geographical trends in this market? Which regions/countries are expected to offer significant growth opportunities for the manufacturers operating in the Cote d'Ivoire IVD market?
- Who are the major players in the Cote d'Ivoire IVD market? What are their specific product offerings in this market?
- What are the recent strategic developments in the Cote d'Ivoire IVD market? What are the impacts of these strategic developments on the market?
Key Topics Covered:
1. Market Definition & Scope
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection and Validation
2.3. Market Sizing and Forecast
2.4. Assumptions for the Study
3. Executive Summary
3.1. Overview
3.2. Segmental Analysis
3.3. Regional Analysis
3.4. Key Players & Competitive Scenario
4. Market Insights
4.1. Overview
4.2. Factors Affecting Market Growth
4.2.1. Drivers
4.2.1.1. Increasing Burden of Infectious Diseases
4.2.1.2. Rising Government Support and International Aid
4.2.1.3. Advancements In Diagnostic Technologies
4.2.1.4. Rising Health Awareness and Population Growth
4.2.2. Restraints
4.2.2.1. High Costs of Advanced Technologies
4.2.2.2. Limited Healthcare Infrastructure
4.2.3. Opportunities
4.2.3.1. Public-Private Partnerships (PPP)
4.2.3.2. Rising Demand for Molecular Diagnostics
4.2.3.3. Telemedicine and Point-of-Care Testing
4.2.3.4. Rising Awareness of Early Diagnosis
4.2.4. Challenges
4.2.4.1. Economic Constraints
4.2.4.2. Supply Chain and Logistics Issues
4.3. Regulatory Analysis
4.3.1. Regulatory Authority
4.3.2. Regulatory Framework
5. Cote d'Ivoire IVD Market Assessment - by Offering
5.1. Overview
5.2. Reagents & Kits
5.3. Instruments
5.4. Software & Services
6. Cote d'Ivoire IVD Market Assessment - by Technology
6.1. Overview
6.2. Immunoassay/Immunochemistry
6.3. Molecular Diagnostics
6.4. Point-of-Care Diagnostics
6.5. Biochemistry/Clinical Chemistry
6.6. Whole Blood Glucose Monitoring
6.7. Hematology
6.8. Microbiology
6.9. Coagulation & Hemostasis
6.10. Other IVD Technologies
7. Cote d'Ivoire IVD Market Assessment - by Application
7.1. Overview
7.2. Infectious Diseases
7.3. Oncology
7.4. Cardiology
7.5. Nephrology
7.6. Diabetes
7.7. Autoimmune Disorders
7.8. Other Applications
8. Cote d'Ivoire IVD Market Assessment - by Diagnostic Approach
8.1. Overview
8.2. Laboratory Testing
8.3. Point-of-Care Testing
8.4. OTC/Self-Testing
9. Cote d'Ivoire IVD Market Assessment - by End User
9.1. Overview
9.2. Diagnostic Laboratories
9.3. Hospitals & Clinics
9.4. Home Healthcare
9.5. Other End Users
10. Competitive Landscape
10.1. Overview
10.2. Key Growth Strategies
10.3. Competitive Benchmarking
10.4. Competitive Dashboard
10.4.1. Industry Leaders
10.4.2. Market Differentiators
10.4.3. Vanguards
10.4.4. Emerging Companies
10.5. Market Share/Ranking Analysis, by the Key Players, 2023
11. Company Profiles
- Abbott Laboratories (U.S.)
- Becton
- Dickinson and Company (U.S.)
- bioMerieux SA (France)
- Danaher Corporation (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- QIAGEN N.V. (Netherlands)
- Siemens Healthineers AG (Germany)
- Thermo Fisher Scientific Inc. (U.S.)
- Bio-Rad Laboratories Inc. (U.S.)
- Illumina Inc. (U.S.)
- Shenzhen Mindray Bio-Medical Electronics Co. Ltd (China)
- The Cote d'Ivoire Medical Research Institute (KEMRI)
- Biovet Ltd. (India)
- Laboratories & Allied Ltd. (Kenya)
For more information about this report visit https://www.researchandmarkets.com/r/oxc7ep
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
